<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01769248</url>
  </required_header>
  <id_info>
    <org_study_id>FNAFNBmucin</org_study_id>
    <nct_id>NCT01769248</nct_id>
  </id_info>
  <brief_title>Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle</brief_title>
  <acronym>MUCIN</acronym>
  <official_title>Randomized Prospective Trial of EUS-FNA Versus EUS-FNB Using a Novel Core Biopsy Needle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving
      the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate
      - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes. This has
      traditionally been done with fine needle aspirate where a needle is inserted into the tumor
      and potentially malignant cells are extracted for microscopic analysis. More recently, a
      needle that allows a tissue biopsy for histologic analysis has been FDA approved.

      The Echotip Procore (Cook Medical) core biopsy needle (ETP), has been demonstrated to provide
      excellent efficacy for core biopsy samples. Final diagnostic yield using this needle ranges
      from 80-90% and appears to be significantly greater than EUS-FNA for lesions requiring
      histology for diagnosis. However, there is currently only limited data from prospective
      studies comparing EUS-FNA to EUS-FNB with the ETP needle. The investigators propose a
      randomized, prospective, cross-over study comparing diagnostic accuracy of EUS-FNA to
      EUS-FNB.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endoscopic ultrasound (EUS) is paramount in the diagnosis and evaluation of cancers involving
      the gastrointestinal tract. EUS allows for the acquisition of cellular (fine needle aspirate
      - FNA) or tissue biopsy (fine needle biopsy - FNB) for diagnostic purposes. This has
      traditionally been done with fine needle aspirate where a needle is inserted into the tumor
      and potentially malignant cells are extracted for microscopic analysis. More recently, a
      needle that allows a tissue biopsy for histologic analysis has been FDA approved.

      We will compare tissue samples obtained by standard FNA to FNB with a sample size of 140
      patients with the primary outcome being diagnostic yield. Each patient will be randomized to
      FNA or FNA. If after 3 passes the on-site evaluation remains inadequate, the endoscopist will
      crossover to the other arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic Yield of EUS-FNB and EUS-FNA</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Specimen Adequacy as Assessed by Rapid-onsite Evaluation of FNA and FNB</measure>
    <time_frame>1 year</time_frame>
    <description>The investigators' secondary outcome will assess the ability to obtain an adequate specimen for in room cytologic evaluation as determined by our cytopathologist. This will be defined as a sample that is representative (not necessarily diagnostic) of the lesion in question. This will be expressed as a percentage and compared between FNA and FNB</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%)</measure>
    <time_frame>1 yr</time_frame>
    <description>As above. Crossover to FNA or FNB occurs after 3 passes without adequate material</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Lymphadenopathy</condition>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <arm_group>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>fine needle aspiration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fine needle biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fine needle aspiration</intervention_name>
    <description>Fine needle aspiration</description>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <other_name>Echo Tip FNA Needle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fine needle biopsy</intervention_name>
    <description>FNB</description>
    <arm_group_label>Fine needle aspiration</arm_group_label>
    <arm_group_label>Fine needle biopsy</arm_group_label>
    <other_name>Echo Tip Procore</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 3.1.1 All patients referred for EUS tissue sampling who provide informed consent

        Exclusion Criteria:

          -  3.2.1 Coagulopathy which is not corrected

        3.2.2 Diagnostic EUS determines lesion is not amenable to FNA or FNB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinadh Komanduri</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffit Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2013</study_first_submitted>
  <study_first_submitted_qc>January 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2013</study_first_posted>
  <results_first_submitted>March 5, 2015</results_first_submitted>
  <results_first_submitted_qc>March 5, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 18, 2015</results_first_posted>
  <last_update_submitted>December 19, 2017</last_update_submitted>
  <last_update_submitted_qc>December 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Sri Komanduri</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>EUS</keyword>
  <keyword>FNA</keyword>
  <keyword>FNB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
    <mesh_term>Lymphadenopathy</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fine Needle Aspiration (FNA)</title>
          <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration using endoscopic ultrasound-FNA needles. This was the standard of care arm</description>
        </group>
        <group group_id="P2">
          <title>Fine Needle Biopsy (FNB)</title>
          <description>Fine Needle biopsy
Fine Needle biopsy: FNB, test arm for core biopsies, endoscopic ultrasound-FNB</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Participants Who Crossed-over</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="58"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fine Needle Aspiration</title>
          <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration</description>
        </group>
        <group group_id="B2">
          <title>Fine Needle Biopsy</title>
          <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="140"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.7" spread="14.4"/>
                    <measurement group_id="B2" value="64.1" spread="14.4"/>
                    <measurement group_id="B3" value="63.8" spread="14.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="66"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Diagnostic Yield of EUS-FNB and EUS-FNA</title>
        <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fine Needle Aspiration</title>
            <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration</description>
          </group>
          <group group_id="O2">
            <title>Fine Needle Biopsy</title>
            <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
          </group>
        </group_list>
        <measure>
          <title>Diagnostic Yield of EUS-FNB and EUS-FNA</title>
          <description>The investigators' primary outcome measure will assess the diagnostic yield (percentage of patients with a diagnosis) of EUS-FNB (fine-needle biopsy) to provide a final diagnosis of the lesion being sampled. This will be expressed as a percentage.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1"/>
                    <measurement group_id="O2" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Specimen Adequacy as Assessed by Rapid-onsite Evaluation of FNA and FNB</title>
        <description>The investigators' secondary outcome will assess the ability to obtain an adequate specimen for in room cytologic evaluation as determined by our cytopathologist. This will be defined as a sample that is representative (not necessarily diagnostic) of the lesion in question. This will be expressed as a percentage and compared between FNA and FNB</description>
        <time_frame>1 year</time_frame>
        <population>Patients with pancreatic and non-pancreatic lesions receiving EUS-FNA and EUS-FNB.</population>
        <group_list>
          <group group_id="O1">
            <title>Fine Needle Aspiration</title>
            <description>fine needle aspiration
Fine needle aspiration: Fine needle aspiration</description>
          </group>
          <group group_id="O2">
            <title>Fine Needle Biopsy</title>
            <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
          </group>
        </group_list>
        <measure>
          <title>Specimen Adequacy as Assessed by Rapid-onsite Evaluation of FNA and FNB</title>
          <description>The investigators' secondary outcome will assess the ability to obtain an adequate specimen for in room cytologic evaluation as determined by our cytopathologist. This will be defined as a sample that is representative (not necessarily diagnostic) of the lesion in question. This will be expressed as a percentage and compared between FNA and FNB</description>
          <population>Patients with pancreatic and non-pancreatic lesions receiving EUS-FNA and EUS-FNB.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0"/>
                    <measurement group_id="O2" value="82.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%)</title>
        <description>As above. Crossover to FNA or FNB occurs after 3 passes without adequate material</description>
        <time_frame>1 yr</time_frame>
        <population>Participants receiving alternative tissue acquisition method when initial three passes with either EUS-FNA or EUS-FNB failed to provide an adequate specimen.</population>
        <group_list>
          <group group_id="O1">
            <title>Fine Needle Aspiration to Fine Needle Biopsy</title>
            <description>fine needle aspiration to fine needle biopsy
EUS-FNA to EUS-FNB</description>
          </group>
          <group group_id="O2">
            <title>Fine Needle Biopsy to Fine Needle Aspiration</title>
            <description>Fine needle biopsy to fine needle aspiration
EUS-FNB to EUS-FNA</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients in Whom a Diagnosis is Achieved After Crossover (%)</title>
          <description>As above. Crossover to FNA or FNB occurs after 3 passes without adequate material</description>
          <population>Participants receiving alternative tissue acquisition method when initial three passes with either EUS-FNA or EUS-FNB failed to provide an adequate specimen.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.4"/>
                    <measurement group_id="O2" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fine Needle Aspiration</title>
          <description>Fine needle aspiration: Fine needle aspiration</description>
        </group>
        <group group_id="E2">
          <title>Fine Needle Biopsy</title>
          <description>Fine needle biopsy
Fine needle biopsy: FNB</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Srinadh Komanduri</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-0484</phone>
      <email>koman1973@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

